SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties

Kihoon Han, J. Lloyd Holder, Christian P. Schaaf, Hui Lu, Hongmei Chen, Hyojin Kang, Jianrong Tang, Zhenyu Wu, Shuang Hao, Sau Wai Cheung, Peng Yu, Hao Sun, Amy M. Breman, Ankita Patel, Hui Chen Lu, Huda Y. Zoghbi

Research output: Contribution to journalArticle

180 Citations (Scopus)

Abstract

Mutations in SHANK3 and large duplications of the region spanning SHANK3 both cause a spectrum of neuropsychiatric disorders, indicating that proper SHANK3 dosage is critical for normal brain function. However, SHANK3 overexpression per se has not been established as a cause of human disorders because 22q13 duplications involve several genes. Here we report that Shank3 transgenic mice modelling a human SHANK3 duplication exhibit manic-like behaviour and seizures consistent with synaptic excitatory/inhibitory imbalance. We also identified two patients with hyperkinetic disorders carrying the smallest SHANK3-spanning duplications reported so far. These findings indicate that SHANK3 overexpression causes a hyperkinetic neuropsychiatric disorder. To probe the mechanism underlying the phenotype, we generated a Shank3 in vivo interactome and found that Shank3 directly interacts with the Arp2/3 complex to increase F-actin levels in Shank3 transgenic mice. The mood-stabilizing drug valproate, but not lithium, rescues the manic-like behaviour of Shank3 transgenic mice raising the possibility that this hyperkinetic disorder has a unique pharmacogenetic profile.

Original languageEnglish
Pages (from-to)72-77
Number of pages6
JournalNature
Volume503
Issue number7474
DOIs
Publication statusPublished - 2013 Oct 28
Externally publishedYes

Fingerprint

Pharmacogenetics
Transgenic Mice
Actin-Related Protein 2-3 Complex
Valproic Acid
Lithium
Actins
Seizures
Phenotype
Mutation
Brain
Pharmaceutical Preparations
Genes

ASJC Scopus subject areas

  • General

Cite this

Han, K., Holder, J. L., Schaaf, C. P., Lu, H., Chen, H., Kang, H., ... Zoghbi, H. Y. (2013). SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. Nature, 503(7474), 72-77. https://doi.org/10.1038/nature12630

SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. / Han, Kihoon; Holder, J. Lloyd; Schaaf, Christian P.; Lu, Hui; Chen, Hongmei; Kang, Hyojin; Tang, Jianrong; Wu, Zhenyu; Hao, Shuang; Cheung, Sau Wai; Yu, Peng; Sun, Hao; Breman, Amy M.; Patel, Ankita; Lu, Hui Chen; Zoghbi, Huda Y.

In: Nature, Vol. 503, No. 7474, 28.10.2013, p. 72-77.

Research output: Contribution to journalArticle

Han, K, Holder, JL, Schaaf, CP, Lu, H, Chen, H, Kang, H, Tang, J, Wu, Z, Hao, S, Cheung, SW, Yu, P, Sun, H, Breman, AM, Patel, A, Lu, HC & Zoghbi, HY 2013, 'SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties', Nature, vol. 503, no. 7474, pp. 72-77. https://doi.org/10.1038/nature12630
Han, Kihoon ; Holder, J. Lloyd ; Schaaf, Christian P. ; Lu, Hui ; Chen, Hongmei ; Kang, Hyojin ; Tang, Jianrong ; Wu, Zhenyu ; Hao, Shuang ; Cheung, Sau Wai ; Yu, Peng ; Sun, Hao ; Breman, Amy M. ; Patel, Ankita ; Lu, Hui Chen ; Zoghbi, Huda Y. / SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties. In: Nature. 2013 ; Vol. 503, No. 7474. pp. 72-77.
@article{f57afc49bf6c41878884ad25cc2dfd78,
title = "SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties",
abstract = "Mutations in SHANK3 and large duplications of the region spanning SHANK3 both cause a spectrum of neuropsychiatric disorders, indicating that proper SHANK3 dosage is critical for normal brain function. However, SHANK3 overexpression per se has not been established as a cause of human disorders because 22q13 duplications involve several genes. Here we report that Shank3 transgenic mice modelling a human SHANK3 duplication exhibit manic-like behaviour and seizures consistent with synaptic excitatory/inhibitory imbalance. We also identified two patients with hyperkinetic disorders carrying the smallest SHANK3-spanning duplications reported so far. These findings indicate that SHANK3 overexpression causes a hyperkinetic neuropsychiatric disorder. To probe the mechanism underlying the phenotype, we generated a Shank3 in vivo interactome and found that Shank3 directly interacts with the Arp2/3 complex to increase F-actin levels in Shank3 transgenic mice. The mood-stabilizing drug valproate, but not lithium, rescues the manic-like behaviour of Shank3 transgenic mice raising the possibility that this hyperkinetic disorder has a unique pharmacogenetic profile.",
author = "Kihoon Han and Holder, {J. Lloyd} and Schaaf, {Christian P.} and Hui Lu and Hongmei Chen and Hyojin Kang and Jianrong Tang and Zhenyu Wu and Shuang Hao and Cheung, {Sau Wai} and Peng Yu and Hao Sun and Breman, {Amy M.} and Ankita Patel and Lu, {Hui Chen} and Zoghbi, {Huda Y.}",
year = "2013",
month = "10",
day = "28",
doi = "10.1038/nature12630",
language = "English",
volume = "503",
pages = "72--77",
journal = "Nature Cell Biology",
issn = "1465-7392",
publisher = "Nature Publishing Group",
number = "7474",

}

TY - JOUR

T1 - SHANK3 overexpression causes manic-like behaviour with unique pharmacogenetic properties

AU - Han, Kihoon

AU - Holder, J. Lloyd

AU - Schaaf, Christian P.

AU - Lu, Hui

AU - Chen, Hongmei

AU - Kang, Hyojin

AU - Tang, Jianrong

AU - Wu, Zhenyu

AU - Hao, Shuang

AU - Cheung, Sau Wai

AU - Yu, Peng

AU - Sun, Hao

AU - Breman, Amy M.

AU - Patel, Ankita

AU - Lu, Hui Chen

AU - Zoghbi, Huda Y.

PY - 2013/10/28

Y1 - 2013/10/28

N2 - Mutations in SHANK3 and large duplications of the region spanning SHANK3 both cause a spectrum of neuropsychiatric disorders, indicating that proper SHANK3 dosage is critical for normal brain function. However, SHANK3 overexpression per se has not been established as a cause of human disorders because 22q13 duplications involve several genes. Here we report that Shank3 transgenic mice modelling a human SHANK3 duplication exhibit manic-like behaviour and seizures consistent with synaptic excitatory/inhibitory imbalance. We also identified two patients with hyperkinetic disorders carrying the smallest SHANK3-spanning duplications reported so far. These findings indicate that SHANK3 overexpression causes a hyperkinetic neuropsychiatric disorder. To probe the mechanism underlying the phenotype, we generated a Shank3 in vivo interactome and found that Shank3 directly interacts with the Arp2/3 complex to increase F-actin levels in Shank3 transgenic mice. The mood-stabilizing drug valproate, but not lithium, rescues the manic-like behaviour of Shank3 transgenic mice raising the possibility that this hyperkinetic disorder has a unique pharmacogenetic profile.

AB - Mutations in SHANK3 and large duplications of the region spanning SHANK3 both cause a spectrum of neuropsychiatric disorders, indicating that proper SHANK3 dosage is critical for normal brain function. However, SHANK3 overexpression per se has not been established as a cause of human disorders because 22q13 duplications involve several genes. Here we report that Shank3 transgenic mice modelling a human SHANK3 duplication exhibit manic-like behaviour and seizures consistent with synaptic excitatory/inhibitory imbalance. We also identified two patients with hyperkinetic disorders carrying the smallest SHANK3-spanning duplications reported so far. These findings indicate that SHANK3 overexpression causes a hyperkinetic neuropsychiatric disorder. To probe the mechanism underlying the phenotype, we generated a Shank3 in vivo interactome and found that Shank3 directly interacts with the Arp2/3 complex to increase F-actin levels in Shank3 transgenic mice. The mood-stabilizing drug valproate, but not lithium, rescues the manic-like behaviour of Shank3 transgenic mice raising the possibility that this hyperkinetic disorder has a unique pharmacogenetic profile.

UR - http://www.scopus.com/inward/record.url?scp=84887404798&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887404798&partnerID=8YFLogxK

U2 - 10.1038/nature12630

DO - 10.1038/nature12630

M3 - Article

C2 - 24153177

AN - SCOPUS:84887404798

VL - 503

SP - 72

EP - 77

JO - Nature Cell Biology

JF - Nature Cell Biology

SN - 1465-7392

IS - 7474

ER -